Home > Anti-aging Research > Zyflamend

Zyflamend

Specific Recommendation:

• Zyflamend at Amazon.com

News and Research:

• 8 natural pain relievers - MSNBC, 9/14/08 - "Capsaicin: For arthritis, shingles, or neuropathy ... InflaThera or Zyflamend: For arthritis ... Aquamin: For osteoarthritis ... SAM-e (S adenosylmethionine): For osteoarthritis ... Fish oil: For joint pain from arthritis or autoimmune disorders ... Methylsulfonyl-methane (MSM): For osteoarthritis"
• Herbal extract may treat prostate cancer - MSNBC, 11/27/05 - "Zyflamend has the ability, in culture at least, to reduce prostate cancer cell growth by as much as 78 percent and induce cancer cell death or “apoptosis,”"
• Herbal COX Inhibitor Acts Against Prostate Cancer Cells - Medscape, 11/25/05
• Columbia Study Suggests Benefits Of Herbal Extract In Early Treatment Of Prostate Cancer - Science Daily, 11/13/05 - "Zyflamend®, a unique herbal extract preparation, suppresses the growth of prostate cancer cells and induces prostate cancer cells to self-destruct via a process called “apoptosis"
• Herb Mix Nixes Prostate Cancer in Lab - WebMD, 12/13/02 - "A number of recent studies point to COX-2 as an important factor in cancer-cell growth. In the Columbia studies, Zyflamend decreased COX-2 activity about as well as a potent COX-2-inhibiting drug ... The herbal mix is called Zyflamend, from New Chapter Inc., and has 10 herbs: holy basil, turmeric, ginger, green tea, rosemary, hu zhang, Chinese goldthread, barberry, oregano, and Scutellaria biacalensis"

Abstracts:

• Zyflamend, a Combination of Herbal Extracts, Attenuates Tumor Growth in Murine Xenograft Models of Prostate Cancer - Nutr Cancer. 2012 Jun 4 - "Prostate cancer (PrC) is the second deadliest cancer of males in the United States Hormone deprivation therapy (HDT), a common therapy for advanced forms of the disease, results in tumor regression; unfortunately, tumors inevitably become castrate-resistant ... Zyflamend® is a combination of extracts from multiple herbs, each with reported anticancer properties. Zyflamend can inhibit growth of various PrC cell lines, but no studies have investigated its potential use in vivo using a model of castrate-resistant PrC. In this study, oral doses of Zyflamend at human equivalent doses inhibited androgen-dependent and castrate-resistant tumor growth in a mouse model that mimics advanced stages of the disease, and reduced the expression of a number of biomarkers linked to PrC progression including pAKT, prostate specific antigen, histone deacetylases, and androgen receptor. In summary, this is the first article to report that Zyflamend, when provided at human equivalent doses, can potentiate the effects of hormone deprivation on tumor regression and growth inhibition of androgen-dependent and castrate-resistant PrC tumors in vivo"
• Zyflamend Reduces the Expression of Androgen Receptor in a Model of Castrate-Resistant Prostate Cancer - Nutr Cancer. 2011 Sep 29 - "These results demonstrated that Zyflamend inhibited IGF-1-stimulated cell growth, IGF-1R expression, and androgen receptor expression and its nuclear localization, but these effects were not dependent upon phosphatidylinositol 3-kinase/pAKT signaling. In conclusion, Zyflamend decreased cell proliferation and inhibited IGF-1R and androgen receptor expression in a phosphatidylinositol 3-kinase/pAKT independent manner"
• Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets - Int J Cancer. 2011 Sep 20. doi: 10.1002/ijc.26442 - "Zyflamend inhibited the proliferation of pancreatic cancer cell lines regardless of p53 status and also enhanced gemcitabine-induced apoptosis. This finding correlated with inhibition of NF-kB activation by Zyflamend and suppression of cyclin D1, c-myc, COX-2, Bcl-2, IAP, survivin, VEGF, ICAM-1, and CXCR4. In nude mice, oral administration of Zyflamend alone significantly inhibited the growth of orthotopically transplanted human pancreatic tumors, and when combined with gemcitabine, further enhanced the antitumor effects. Immunohistochemical and Western blot analyses of tumor tissue showed that the suppression of pancreatic cancer growth correlated with inhibition of proliferation index marker (Ki-67), COX-2, MMP-9, NF-kB, and VEGF. Overall, these results suggest that the concentrated multiherb product Zyflamend alone can inhibit the growth of human pancreatic tumors and, in addition, can sensitize pancreatic cancers to gemcitabine through the suppression of multiple targets linked to tumorigenesis"
• Zyflamend Mediates Therapeutic Induction of Autophagy to Apoptosis in Melanoma Cells - Nutr Cancer. 2011 Jul 11 - "Zyflamend, a unique multiherbal extract preparation, is a promising antiinflammatory agent that has also been suggested to regulate multiple pathways in cancer progression. As Zyflamend contains ingredients that can suppress tumor cell proliferation, invasion, angiogenesis, and metastasis through regulation of inflammatory pathway products, we hypothesized that this preparation might inhibit melanoma proliferation. To test this hypothesis, we studied the effect of Zyflamend on melanoma proliferation. Here, we present that Zyflamend inhibits melanoma growth by regulating the autophagy-apoptosis switch. Based on the responsible molecular mechanisms of Zyflamend, our study highlights the importance of the use of herbal preparations for the prevention and treatment of cancer"
• Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa B-regulated gene products - Nutr Cancer. 2007;57(1):78-87 - "Zyflamend inhibited receptor activator of NF-kappa B ligand-induced osteoclastogenesis, suppressed tumor necrosis factor (TNF)-induced invasion, and potentiated the cytotoxicity induced by TNF and chemotherapeutic agents, all of which are known to require NF-kappa B activation. Zyflamend suppressed NF-kappa B activation induced by both TNF and cigarette smoke condensate. The expression of NF-kappa B-regulated gene products involved in antiapoptosis (inhibitor-of-apoptosis protein 1/2, Bcl-2, Bcl-xL, FADD-like interleukin-1betaconverting enzyme/caspase-8 inhibitory protein, TNF receptor-associated factor-1, and survivin) and angiogenesis (vascular endothelial growth factor, cyclooxygenase-2, intercellular adhesion molecule, and matrix metalloproteinase-9) was also down-regulated by Zyflamend. This correlated with potentiation of cell death induced by TNF and chemotherapeutic agents. Overall, our results indicate that Zyflamend suppresses osteoclastogenesis, inhibits invasion, and potentiates cytotoxicity through down-regulation of NF-kappa B activation and NF-kappa B-regulated gene products"